Effective treatment of advanced multiple myeloma refractory to alkylating agents.

Abstract

Twenty-nine patients with advanced refractory multiple myeloma were treated with intermittent high-dose dexamethasone in combination with four-day infusions of vincristine and doxorubicin. Rapid and marked tumor-mass reduction (greater than 75 per cent) was noted in 14 of 20 patients whose disease was resistant to alkylating agents and in 3 of 9 patients with additional resistance to doxorubicin--a result far superior to those in previous trials with similar patients. In responsive patients, remissions were of excellent quality, and survival was significantly longer than in unresponsive patients.

• Authors: B Barlogie, L Smith, R Alexanian
• Journal: The New England journal of medicine (N Engl J Med) Vol. 310 Issue 21 Pg. 1353-6 (May 24 1984) ISSN: 0028-4793 [Print] United States
• PMID: 6546971 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Alkylating Agents
• RNA, Neoplasm
• Vincristine
• Dexamethasone
• Doxorubicin
• Cyclophosphamide
• Melphalan
• Prednisone

Topics

• Alkylating Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Cyclophosphamide (adverse effects, therapeutic use)
• Dexamethasone (administration & dosage, adverse effects, therapeutic use)
• Doxorubicin (administration & dosage, adverse effects, therapeutic use)
• Drug Resistance
• Humans
• Melphalan (therapeutic use)
• Middle Aged
• Multiple Myeloma (drug therapy)
• Plasma Cells (analysis)
• Prednisone (adverse effects, therapeutic use)
• RNA, Neoplasm (analysis)
• Vincristine (administration & dosage, adverse effects, therapeutic use)